Table 3.
The efficacy of different treatment groups between CR/PR and SD/PD.
Group 1 |
Group 2 |
|||||
---|---|---|---|---|---|---|
UX first-line therapy (n = 9) | UX second-line or above therapy (n = 31) | P-value | UX first-line therapy (n = 9) | NP first-line therapy n = 60 | P-value | |
CR/PR | 3 | 5 | 0.348 | 3 | 11 | 0.373 |
SD/PD | 6 | 26 | 6 | 49 |
CR complete response, PR partial response, SD stable disease, PD progressive disease, UX (Utidelone plus Capecitabine); NP (Vinorelbine plus Cisplatin).